Babich, John

PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer

Kratochwil, C., Giesel, F. L., Leotta, K., Eder, M., Hoppe-Tich, T., Youssoufian, H., Kopka, K., Babich, J. W., & Haberkorn, U. (2015) · Journal of Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 117

Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial

Matthay, K. K., Weiss, B., Villablanca, J. G., Maris, J. M., Yanik, G. A., DuBois, S. G., Stubbs, J., Groshen, S., Tsao-Wei, D., Hawkins, R., et al. (2012) · Journal of Nuclear Medicine

Neuroblastoma Research and TreatmentsRadiopharmaceutical Chemistry and Applications

Cited by 67

A Consensus Time for Performing Quality Control of 225Ac-Labeled Radiopharmaceuticals

Kelly, J. M., Amor-Coarasa, A., Sweeney, E., Wilson, J. J., Causey, P. W., & Babich, J. (2021)

Radiopharmaceutical Chemistry and ApplicationsRadioactive Decay and Measurement Techniques

Cited by 11

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Tagawa, S. T., Osborne, J., Fernandez, E., Thomas, C., Niaz, M. J., Ciriaco, A., Vallabhajosula, S., Vlachostergios, P. J., Molina, A. M., Sternberg, C. N., et al. (2020) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 10